A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Clinical Trials, Metastatic Castration Resistant Prostate Cancer (MCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05652686
Phase: PHASE1|PHASE2
Trial Summary: PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47). This is an open label, Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and prelimin – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Phanes Therapeutics
Acronym:

Pin It on Pinterest